Abnormal liver tests in patients with SARS-CoV-2 or influenza - prognostic similarities and temporal disparities.
ALKP, alkaline phosphatase
ALT, alanine transaminase
AST, aspartate transaminase
BOSmin, minimal blood oxygen saturation
COVID-19
COVID-19, coronavirus disease 2019
CRP, C-reactive protein
GGT, gamma-glutamyl transferase
Liver injury
Respiratory tract infections
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
SBPmin, minimal systolic blood pressure
WBC count, white blood cell count
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
11
2020
revised:
25
01
2021
accepted:
15
02
2021
pubmed:
2
3
2021
medline:
2
3
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
Abnormal liver tests are common in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but a possible direct role of the virus in liver injury and its association with short-term outcomes are controversial. Therefore, we aimed to compare the pattern of abnormal liver tests in patients with SARS-CoV-2 with those of patients infected with influenza, a non-hepatotropic respiratory virus, and their association with worse outcomes during hospitalisation. We performed a retrospective cohort study of 1,737 hospitalised patients (865 with influenza and 872 with SARS-CoV-2) in a tertiary medical centre. We defined abnormal liver tests as alanine transaminase or aspartate transaminase ≥40 IU/ml at any time-point during hospitalisation. Abnormal liver tests were mild to moderate in most patients regardless of infection type, but the majority of patients with influenza had a transaminase peak earlier during hospitalisation compared with patients with SARS-CoV-2. Abnormal liver tests correlated with markers of severe disease in either influenza or SARS-CoV-2 infections, and were associated with death, occurring mainly in patients with severe liver test abnormalities (>200 IU/L) (38.7% and 60% of patients with influenza or SARS-CoV-2, respectively). In multivariate analysis, controlling for age, sex, lymphopaenia, and C-reactive protein, liver test abnormalities remained significantly associated with death for influenza (odds ratio 4.344; 95% CI 2.218-8.508) and SARS-CoV-2 (odds ratio 3.898; 95% CI 2.203-6.896). These results were confirmed upon propensity score matching. Abnormal liver tests during hospitalisation with SARS-CoV-2 or influenza infections are common, may differ in their time course, and reflect disease severity. They are associated with worse outcomes, mainly in patients with severe liver test abnormalities, regardless of infection type. Coronavirus disease 2019 (COVID-19) is a serious global health pandemic, the causative agent of which is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Abnormal liver tests are common among SARS-CoV-2 infected patients and are often associated with worse outcomes. Herein, we compare the pattern of abnormal liver tests and their association with disease severity between 2 major non-hepatotropic respiratory viruses: SARS-CoV-2 and influenza. We show that abnormal liver tests are common in both infections, may slightly differ in their kinetics, and are associated with worse outcomes, especially in patients with severe liver test abnormalities. These results strongly suggest that abnormal liver tests in SARS-CoV-2 patients reflect disease severity, rather than a virus-mediated direct liver injury, and should be closely followed in admitted patients.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Abnormal liver tests are common in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but a possible direct role of the virus in liver injury and its association with short-term outcomes are controversial. Therefore, we aimed to compare the pattern of abnormal liver tests in patients with SARS-CoV-2 with those of patients infected with influenza, a non-hepatotropic respiratory virus, and their association with worse outcomes during hospitalisation.
METHODS
METHODS
We performed a retrospective cohort study of 1,737 hospitalised patients (865 with influenza and 872 with SARS-CoV-2) in a tertiary medical centre. We defined abnormal liver tests as alanine transaminase or aspartate transaminase ≥40 IU/ml at any time-point during hospitalisation.
RESULTS
RESULTS
Abnormal liver tests were mild to moderate in most patients regardless of infection type, but the majority of patients with influenza had a transaminase peak earlier during hospitalisation compared with patients with SARS-CoV-2. Abnormal liver tests correlated with markers of severe disease in either influenza or SARS-CoV-2 infections, and were associated with death, occurring mainly in patients with severe liver test abnormalities (>200 IU/L) (38.7% and 60% of patients with influenza or SARS-CoV-2, respectively). In multivariate analysis, controlling for age, sex, lymphopaenia, and C-reactive protein, liver test abnormalities remained significantly associated with death for influenza (odds ratio 4.344; 95% CI 2.218-8.508) and SARS-CoV-2 (odds ratio 3.898; 95% CI 2.203-6.896). These results were confirmed upon propensity score matching.
CONCLUSIONS
CONCLUSIONS
Abnormal liver tests during hospitalisation with SARS-CoV-2 or influenza infections are common, may differ in their time course, and reflect disease severity. They are associated with worse outcomes, mainly in patients with severe liver test abnormalities, regardless of infection type.
LAY SUMMARY
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a serious global health pandemic, the causative agent of which is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Abnormal liver tests are common among SARS-CoV-2 infected patients and are often associated with worse outcomes. Herein, we compare the pattern of abnormal liver tests and their association with disease severity between 2 major non-hepatotropic respiratory viruses: SARS-CoV-2 and influenza. We show that abnormal liver tests are common in both infections, may slightly differ in their kinetics, and are associated with worse outcomes, especially in patients with severe liver test abnormalities. These results strongly suggest that abnormal liver tests in SARS-CoV-2 patients reflect disease severity, rather than a virus-mediated direct liver injury, and should be closely followed in admitted patients.
Identifiants
pubmed: 33644724
doi: 10.1016/j.jhepr.2021.100258
pii: S2589-5559(21)00034-3
pmc: PMC7902222
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100258Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest that pertain to this work.
Références
J Hepatol. 2020 Oct;73(4):807-816
pubmed: 32437830
J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):536-8
pubmed: 17033532
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Sci Rep. 2018 Jan 29;8(1):1803
pubmed: 29379110
J Hepatol. 2020 Nov;73(5):1275-1276
pubmed: 32473194
Hepatology. 2004 Feb;39(2):302-10
pubmed: 14767982
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Hepatology. 2020 Nov;72(5):1864-1872
pubmed: 32702162
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Hepatol. 2020 Aug;73(2):455-458
pubmed: 32305291
Clin Liver Dis (Hoboken). 2020 May 21;15(5):175-180
pubmed: 32489653
Liver Int. 2020 Jun;40(6):1321-1326
pubmed: 32239591
Clin Infect Dis. 2020 Nov 5;71(8):1962-1968
pubmed: 32472676
Influenza Other Respir Viruses. 2012 May;6(3):e2-5
pubmed: 21951624
J Hepatol. 2020 Oct;73(4):995-996
pubmed: 32502510
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Hepatol. 2020 Oct;73(4):991-992
pubmed: 32454042
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Aliment Pharmacol Ther. 2020 Sep;52(6):1060-1068
pubmed: 32628793
Clin Chem. 2000 Dec;46(12):2050-68
pubmed: 11106350
Hepatology. 2020 Oct;72(4):1169-1176
pubmed: 32725890
Hepatology. 2020 Sep;72(3):807-817
pubmed: 32473607
Am J Pathol. 2006 Apr;168(4):1057-9
pubmed: 16565481
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143